Jasper Therapeutics (JSPR) is now covered by UBS Group AG. They set a "neutral" rating and a $1.50 price target on the stock.
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference [Yahoo! Finance]
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference
Johnson Fistel, PLLP Begins Investigation on Behalf of Long-Term Shareholders of Jasper Therapeutics, Inc. (JSPR), KBR, Inc. (KBR), LifeMD, Inc. (LFMD), and Lineage, Inc. (LINE)
Jasper Therapeutics (NASDAQ:JSPR) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.